Allurion Technologies, Inc. (NYSE: ALUR) (the “Company” or “Allurion”), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the “January 2025 Warrants”), February 20, 2025 (the “February 2025 Warrants”) and November 12, 2025 (the “November 2025 Warrants” and together with the January 2025 Warrants and the February 2025 Warrants, the “Existing Warrants”), at a reduced exercise price of $1.15 per share. The shares of common stock issuable upon exercise of the January 2025 Warrants and February 2025 Warrants are registered for resale pursuant to the effective registration statement on Form S-3 (File No. 333-286837) and the shares of common stock issuable upon exercise of the November 2025 Warrants are registered for resale pursuant to the effective registration statement on Form S-3 (File No. 333-292660). The aggregate gross proceeds from the exercise of the Existing Warrants is expected to total approximately $3.0 million, before deducting financial advisory fees. The closing of the offering is expected to occur on or about February 25, 2026, subject to satisfaction of customary closing conditions.

Roth Capital Partners is acting as the Company’s financial advisor for this transaction.

In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holders will receive new warrants to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”). The new warrants will be exercisable into an aggregate of up to 5,319,130 shares of common stock, will be exercisable beginning on the effective date of stockholder approval of the shares issuable upon exercise of the new warrants at an exercise price of $1.15 per share, and have a term of exercise equal to five years after the stockholder approval date.

The securities offered in the private placement have not been registered under the 1933 Act, or an applicable exemption under state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company has agreed to file a resale registration statement with the Securities and Exchange Commission to register the resale of the shares of common stock underlying the new warrants issued in the private placement.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Allurion

Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the FDA PMA approved Allurion Gastric Balloon System, featuring the Allurion Smart Capsule—the world’s first and only swallowable, Procedureless^TM gastric balloon for weight loss—with the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

Forward-Looking Statements

This press release contains forward-looking statements that reflect Allurion’s beliefs and assumptions based on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terms, although not all forward-looking statements contain these words. Although Allurion believes it has a reasonable basis for each forward-looking statement contained in this release, these statements involve risks and uncertainties that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.

Forward-looking statements in this press release include, but are not limited to, statements regarding: the expected timing for the closing of this transaction, and the anticipated proceeds therefrom; the timing of stockholder approval of the shares underlying the new warrants; and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to management.

Allurion cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward looking statements are subject to a number of risks and uncertainties, including, among others, the size, timing and completion of the offering, general economic, political and business conditions; the ability of Allurion to obtain and maintain regulatory approval for, and successfully commercialize, the Allurion Gastric Balloon System, including the Allurion Smart Capsule; the timing of, and results from, Allurion’s clinical studies and trials, including with respect to the combination of GLP-1s with the Allurion Smart Capsule; the evolution of the markets in which Allurion competes, including the impact of GLP-1 drugs; the ability of Allurion to maintain its listing on the New York Stock Exchange; a changing regulatory landscape in the highly competitive industry in which Allurion competes; the impact of the imposition of current and potential tariffs and trade negotiations, and those factors discussed under the heading “Risk Factors” in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 27, 2025, and as amended on August 19, 2025, and updated from time to time by its other filings with the SEC, and its Quarterly Report on Form 10-Q filed with the SEC on November 17, 2025. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Allurion undertakes no obligation to update any forward-looking statements to reflect any new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events, other than as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260224024473/en/